Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne (NASDAQ: TECH) will present at four investor conferences in November 2025. Scheduled presentations:

• UBS Global Healthcare — November 10, 2025 at 10:15 AM ET
• Stifel Healthcare — November 11, 2025 at 9:20 AM ET
• Stephens Investment — November 18, 2025 at 8:00 AM CT
• Jefferies Global Healthcare — November 20, 2025 at 12:30 PM GMT

A live webcast will be available via the company's Investor Relations Calendar at https://investors.bio-techne.com/ir-calendar.

Bio-Techne (NASDAQ: TECH) reported first quarter fiscal 2026 results for the period ended September 30, 2025.

Key figures: net sales $286.6M (down 1% YoY), GAAP EPS $0.24 versus $0.21, adjusted EPS $0.42 (flat YoY), and adjusted operating margin 29.9%. GAAP operating income rose 19% to $47.7M and GAAP operating margin improved to 16.6% from 13.8%.

The company completed the divestiture of Exosome Diagnostics (EPI), cited productivity and cost containment gains, and flagged short- and intermediate-term order timing headwinds in its GMP proteins business tied to customer regulatory progress.

Bio-Techne (NASDAQ: TECH) and Nucleai presented SECOMBIT clinical-trial spatial biology data at SITC 2025 showing AI-integrated, high-plex imaging can identify predictive biomarkers in metastatic melanoma.

Researchers profiled 42 pre-treatment biopsies using the COMET platform and a 28-plex mIF panel; analyses linked specific immune cell locations and interactions to progression-free survival, overall survival, and clinical benefit across three treatment arms. The abstract was selected among the top 150 of ~1,200 submissions. Poster #528 and Bio-Techne booth #603 at SITC 2025 will display the data and new spatial biology products including ProximityScope and extended SPYRE portfolio.

ScaleReady (TECH) announced a $300,000 G-Rex Grant awarded to Sonoma Biotherapeutics to accelerate development of a G-Rex based manufacturing process for gene-modified regulatory T cell (Treg) therapies for clinical investigation, targeting autoimmune disorders. The grant supports transition from open-flask methods to closed, scalable G-Rex devices and integration of ProPak GMP cytokines, process analytical technology, and novel closed-system tools from Wilson Wolf.

ScaleReady reports its G-Rex Grant Program has exceeded $40M in no-cost product commitments; individual awards are up to $300,000.

Bio-Techne (NASDAQ: TECH) launched the ProximityScope™ assay on the Leica Biosystems BOND RX staining platform on October 28, 2025, enabling visualization of functional protein-protein interactions in fixed tissue at subcellular resolution.

The assay produces a visual signal only when two proteins are physically close, integrates with ACD's RNAscope Multiomic LS kit for RNA and protein detection on the same section, and automates spatial multiomic workflows via Leica's BOND RX. The workflow will be showcased at SITC, Nov 7-8, 2025 (Booth 603). Bio-Techne reported over $1.2B net sales in fiscal 2025 and about 3,100 employees.

ScaleReady (TECH) and partners awarded four G‑Rex Grants to Children's National Hospital totaling $375,000 to support translation of cell and gene therapies into the clinic.

Grants: $100,000 to Dr. Patrick Hanley for a G‑Rex CAR‑T manufacturing process; $150,000 shared by Drs. Keller and Hanley to move VST and TAAT workflows into G‑Rex M series bioreactors; $75,000 to Dr. Amy Hont for ATTACK TAAT; $50,000 to Dr. Cruz for CAR‑modified TAAT process development.

ScaleReady reports its G‑Rex Grant Program surpassed $40M of no‑cost product commitments and launched a free LEAN Cell & Gene event series.

Bio-Techne (NASDAQ:TECH) and Saguaro Biosciences announced a distribution agreement on October 15, 2025 to expand global access to Saguaro’s non-toxic, wash-free live-cell dyes.

The partnership will use Bio-Techne’s international sales and marketing channels to distribute Saguaro products including ChromaLIVE™, NucleoLIVE™, and MortaLIVE™, targeting researchers in biotech, academia, and large pharma for cell-based assays, viability testing, and phenotypic profiling.

Bio-Techne (NASDAQ: TECH) will host a live conference call and webcast on Wednesday, November 5, 2025 at 8:00 a.m. CST to review first quarter fiscal 2026 financial results.

Live access: dial 1-800-274-8461 or 1-203-518-9814 (international) using Conference ID TECHQ1, or join the webcast at https://investors.bio-techne.com/ir-calendar. A recorded rebroadcast will be available starting 11:00 a.m. CST on November 5, 2025 through 11:00 p.m. CST on December 5, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 and referencing Conference ID 11160247.

Bio-Techne (NASDAQ: TECH) expanded its collaboration with Oxford Nanopore Technologies and broadened commercial rights to develop a portfolio of genetics products on Oxford Nanopore platforms.

The agreement formally extends the partnership through 2032, builds on the March 2025 launch of the AmplideX Nanopore Carrier Plus Kit, and establishes a framework to define and propose future targeted enrichment sequencing kits for screening and diagnosis of heritable genetic disorders.

The companies said the enhancement will streamline coordination on development and commercialization and support Bio-Techne's diagnostics growth strategy by accelerating innovation and portfolio planning.